During the past decade, Centre Hospitalier de Sens conducted 6 clinical trials. In the 10-year time frame, 6 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Centre Hospitalier de Sens" #1 sponsor was "Intergroupe Francophone de Cancerologie Thoracique" with 2 trials, followed by "ARCAGY/ GINECO GROUP" with 1 trials sponsored, "Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie" with 1 trials sponsored, "Celgene" with 1 trials sponsored and "Federation Francophone de Cancerologie Digestive" with 1 trials sponsored. Other sponsors include -2 different institutions and companies that sponsored additional 8 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Centre Hospitalier de Sens" #1 collaborator was "AstraZeneca" with 1 trials as a collaborator, "Groupe Francais De Pneumo-Cancerologie" with 1 trials as a collaborator and "Hoffmann-La Roche" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 3 trials.

According to Clinical.Site data, the most researched conditions in "Centre Hospitalier de Sens" are "Advanced Non Small Cell Lung Cancer" (1 trials), "Atrioventricular Block" (1 trials), "Colonic Adenocarcinoma" (1 trials), "Colorectal Cancer Metastatic" (1 trials) and "Epithelial Ovarian Cancer" (1 trials). Many other conditions were trialed in "Centre Hospitalier de Sens" in a lesser frequency.

Most popular intervention types in "Centre Hospitalier de Sens" are "Drug" (4 trials), "Biological" (1 trials), "Device" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Anti-EGFR agent (cetuximab +/- irinotecan or panitumumab)" (1 trials), "Atezolizumab" (1 trials), "Carboplatin" (1 trials), "Cisplatin" (1 trials) and "FOLFIRI-cetuximab" (1 trials). Other intervention names were less common.

The vast majority of trials in "Centre Hospitalier de Sens" are 7 trials for "All" genders, 1 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Centre Hospitalier de Sens". undefined are not yet recruiting, 3 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 6 completed trials in Centre Hospitalier de Sens, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Centre Hospitalier de Sens, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 5 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".